Pacira SVP Finance sells 6,115 shares at $23.50
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,115 | $23.50 | $144K |
Footnotes (1)
- F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
open-market sale financial
Securities Exchange Act of 1934 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Pacira BioSciences (PCRX) report for Lauren Riker?
Was the Pacira BioSciences (PCRX) insider sale made under a Rule 10b5-1 plan?
What role does Lauren Riker hold at Pacira BioSciences (PCRX) in this Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.